Objective: To study the relationships of molecularly defined lactose malabsorption (LM) and self-reported lactose intolerance (LI) to bone mineral density (BMD) and fractures among Finnish postmenopausal women. Design: A cross-sectional study of two cohorts. Setting: Helsinki University Central Hospital. Subjects: One cohort was population-based and comprised 453 women, aged 62-78 (mean 69) y. Another comprised 52 women, aged 69-85 (mean 75) y, with osteoporotic fractures and 59 control women, aged 69-83 (mean 74) y, without osteoporosis. Methods: A single nucleotide polymorphism of the lactase (LCT) gene at chromosome 2q21-22 was studied. It shows complete association with intestinal disaccharidase activity, with the genotype CC À13 910 meaning adult-type hypolactasia (primary LM) and the genotypes CT À13 910 and TT À13 910 lactose absorption. BMD of the heel was measured by dual-energy X-ray absorptiometry (DXA). Results: In the population-based cohort, 16.0% of women had self-reported LI but only 15.3% of them had the CC À13 910 genotype. Calcium intake from dairy products (P ¼ 0.10) and BMD, adjusted for age, weight, height, exercise, smoking, and estrogen use (P ¼ 0.71) were similar for the genotypes. Women with self-reported LI had reduced calcium intake from dairy products (Po0.0001) but they were more frequent users of calcium supplements than lactose-tolerants (Po0.0001). Adjusted BMD was similar for lactose intolerant and tolerant women (P ¼ 0.60). Of 104 women with previous fracture in the populationbased cohort, 13.5% had the CC À13 910 genotype, which did not differ from the prevalence of 19.3% among 347 women without fractures (P ¼ 0.29). The frequency of the CC À13 910 genotype (23.1%) for 52 women with established osteoporosis was similar as for 59 control women (15.3%) (P ¼ 0.19). Conclusion: Molecularly defined LM and self-reported LI are not risk factors for osteoporosis, if calcium intake from diet and/or supplements remains sufficient. Our study confirms the poor correlation between self-reported LI and LM established by different techniques.
Introduction
Osteoporosis is a multi-factorial disease caused by both genetic and environmental factors (Delmas, 2002) . Calcium has been shown to be an important nutrient in the prevention and treatment of osteoporosis (Birge et al, 1967; Finkenstedt et al, 1986; Stallings et al, 1994) . It is naturally supplied in the form of dairy products that contain lactose. Lactose malabsorption (LM; adult-type hypolactasia), an autosomal recessive condition, is very common in most parts of the world (Sahi et al, 1973) . In subjects with LM, the downregulation of the activity of lactase enzyme occurs after weaning in the intestinal cells to 5-10% of that in infancy. The ability to maintain high lactase activity throughout life is inherited as a dominant single-gene trait. LM can be manifested clinically as lactose intolerance (LI) by flatulence, bloating, distention, diarrhea and abdominal pain leading to decreased intake of milk (and calcium) (Tamm, 1994) . The effect of lactose and lactase enzyme activity on the absorption of calcium is controversial: in some reports decreased calcium absorption is reported in lactase-deficient subjects (Cochet et al, 1983) , but also opposite data exist (Debongnie et al, 1979; Tremaine et al, 1986) . Likewise controversy exists on the role of LI-either self-reported or established by different techniques-as a risk factor of osteoporosis (Corazza et al, 1995; Honkanen et al, 1997; Goulding et al, 1999; Black et al, 2002) . Generally accepted has, however, been the view that if lactose intolerant people significantly reduce their calcium intake, the bone status worsens (Corazza et al, 1995; Honkanen et al, 1997; Goulding et al, 1999; Black et al, 2002) .
The definitive diagnosis of LM is based on the measurement of the disaccharidase enzyme activities and lactase/ saccharase (L/S) ratio in intestinal biopsies (Messer & Dahlqvist, 1966) . This invasive technique has prevented large scale population studies of the effect of LM/absorption on the development of osteoporosis and bone fractures. We have recently identified a single nucleotide polymorphism (SNP), a C to T change residing 13 910 base pairs upstream of the lactase (LCT) gene at chromosome 2q21-22, that shows complete association with the LM. The genotype CC À13 910 in a homozygous form is associated with the LM and the genotypes CT À13 910 and TT À13 910 with lactose absorption (LA) (Enattah et al, 2002) . Further, nearly a 100-fold difference in the mRNA expression of the LCT alleles has been demonstrated in subjects with the CT genotype thus implying that the C (À13 910) T variant may be associated with the transcriptional regulation of the LCT gene (Kuokkanen et al, 2003) . Importantly, the three genotypes perfectly correlate with the level of the disaccharidase activities in intestinal biopsy samples and their L/S ratio (Enattah et al, 2002 , Kuokkanen et al, 2003 , making this SNP suitable for the specific diagnosis of LM in large study samples. This is in agreement with a recent in vitro study by Olds and Sibley (2003) , who reported greater increase in lactase promoter activity by the TÀ13 910 variant using Luciferase reporter construct. In 30 different populations (1360 samples), the frequency of the CC À13 910 genotype has been in agreement with the reported prevalence of LM (unpublished data).
To date, only one report is available from Austria on the relationship of molecularly defined LM to bone mineral density (BMD) and bone fractures in postmenopausal women (Obermayer-Pietsch et al, 2004) . Thus, we decided to study the same relationship among Finnish postmenopausal women. In addition we examined the relationship of self-reported LI to BMD and bone fractures as well as the concordance between self-reported LI and molecularly defined LM.
Subjects and methods

Subjects and study design
The relationship to the CC À13 910 genotype to heel BMD was studied in a population-based group of 453 postmenopausal women. They were a subgroup of a cohort participating in an ongoing intervention study, which is aimed at elucidating the effectiveness of an educational program for the prevention of fractures. A total of 2181 postmenopausal women, aged 60-70 y and living in Southern Finland (Uusimaa region), were initially recruited from the population register between 1996 and 2000. They were randomized either to the educational program (n ¼ 1007) or as controls (n ¼ 1174). After a 1-week educational course at the baseline, the intervention group has been trained repeatedly by group meetings and by information letters. The control group will be followed without any intervention. Any fracture is treated as the primary endpoint of the study.
In the year 2002 all participants were invited to have a heel BMD measurement and to give a blood sample for DNA testing. Subjects of the present study are a random subset of 453 participants in the control group. Only the control group was used to exclude the possible bias caused by the intervention program. The ethics committee of Department of Medicine, Helsinki University Central Hospital approved the study. All participants gave an informed, written consent.
Height and weight were recorded and the participants filled in a questionnaire dealing with health and lifestyle factors. It was asked whether the subject had LI and whether or not she followed a lactose-free diet. Two women did not answer this question. Leisure time physical activity was assessed by asking how many times (duration Z30 min) per week the subjects spent on walking, gymnastics, swimming, bicycling or other sports. All were asked for their smoking history (never smoked, ex-smoker, current smoker). Calcium intake was calculated on the basis of the supply from dairy products only by asking how many portions (a glass for milk, sour milk, yogurt, a slice for cheese) the subject used daily or weekly. The following estimations were used in the calculations: one glass ¼ 1.8 dl; 1 dl of milk, sour milk, and yogurt contains 120 mg of calcium, and one slice of cheese 100 mg. The questionnaire was not validated, but 80% of the daily calcium intake in the Finnish diet originates from dairy products. Any current use of calcium supplements (freely available in health shops and drug stores) was recorded and alcohol consumption was assessed, by asking, how many times and which kind of alcohol drinks (beer, wine, liquor) the subject used weekly. For estrogen use the subjects were categorized as never users, ex-users, current users with a late onset (a few years' use only) or current users with an early onset in the menopause. All subjects were asked for the history of low-energy fractures. Heel BMD adjusted for anthropometric and lifestyle factors were compared across the three genotypes. Similar comparisons were performed between those with and without self-reported LI.
The relationship of the CC À13 190 genotype to established osteoporosis was studied among 111 postmenopausal women. In all, 52 of them (aged 69-85 (mean 75) y) were participants in trials on drug treatment of osteoporosis. Their inclusion criteria were either a vertebral fracture (n ¼ 37) or osteoporosis in terms of the WHO criteria of BMD (a T-score rÀ2.5) (Kanis et al, 1994) at either the lumbar spine or the femoral neck. The T-score indicates, how many standard deviations the patient's BMD differs from the mean peak bone mass of a young healthy adult population of the same gender. In all, 15 of the participants without vertebral fractures had had an extra-vertebral fracture. For comparison, 59 women (aged 69-83 (mean 74) y) who had been excluded from the same trials due to no prevalent vertebral fractures and the BMD not fulfilling the above mentioned WHO criteria, were also studied. Exclusion criteria included metabolic bone disease other than postmenopausal osteoporosis, use of bone-active agents (any previous use of bisphosphonates, concomitant use of oral glucocorticoids, or hormone replacement therapy use less than 6 months before the study), diseases that affect bone turnover, history of gastrointestinal mucosal disorders (erosive gastritis, gastric ulcer or esophagitis), history of a prior thromboembolic disease, liver or kidney disease, insulin-treated diabetes, history of uterus or breast cancer, or uncontrolled hypertension. The frequencies of the CC À13 910 genotype among patients and controls were compared.
DXA measurement
The heel BMD was measured using a densitometer from GE Medical Systems, LUNAR, PIXI (Wisconsin, MA, USA). The precision of the method (coefficient of variation) was 2.0%. The results were expressed as both absolute values and Z-scores, which indicate how many standard deviations the patient's measurement deviates from the mean of an ageand sex-matched healthy population.
Genotyping
Genomic DNA was extracted from samples of peripheral venous blood according to standard procedures, and the DNA fragment spanning the C (À13 910) T variant was amplified using a biotinylated and an unbiotinylated primer (the primers are available upon request). An aliquot 10 ml of the PCR product was captured in a streptavidin coated microtitre well (Labsystems, Finland). The wells were washed, and the bound DNA was denatured as described previously (Syvänen et al, 1993) . Typically, 50 ml of the minisequencing reaction mixture contained 10 pmoles of the minisequencing primers for C (À13 910) T and 0.1 ml of either 3 H-dCTP corresponding to the lactase non-persistence allele (Amersham, UK) or 3 H-dTTP corresponding to the lactase persistence allele, and 0.05 units of DNA polymerase (Dynazyme II, Finnzymes). The microtiter plates were incubated for 20 min at 501C, and the wells were washed. The detection primer was eluted, and the eluted radioactivity was measured in a liquid scintillation counter (Rackbeta 1209, Wallac, Finland). Two parallel minisequencing reactions were carried out for each PCR product.
Statistics
Anthrpometric and lifestyle factors across the LCT genotypes and for lactose-intolerant vs tolerant women were compared using Kruskal-Wallis test. Median with ranges are presented in the tables due to the skewness of the distributions. Categorical variables (smoking, estrogen use, use of calcium supplements, history of fractures) were compared with Fisher's exact test. The relationship between the LCT genotypes and BMD was analyzed using a multiple regression model by adjusting for age, height, weight, smoking, alcohol consumption, current exercise, and estrogen use. Least square means and their standard errors for BMD from the adjusted analysis are presented in the table. The analyses were performed with SPSS version 10.0 and SAS (Version 8.02 for Windows). All tests were performed as two-sided using 0.05 significance level.
Results
The characteristics for subjects with the three genotypes among the population-based cohort of postmenopausal women are given in Table 1 . Calcium intake from dairy products was similar for the genotypes (P ¼ 0.10) as was the use of calcium supplements (P ¼ 0.38). The three genotypes did not differ with respect to heel BMD adjusted for age, weight, height, exercise, smoking, and estrogen use (P ¼ 0.71) ( Table 1 ). The same characteristics for those with and without self-reported LI are given in Table 2 . Calcium intake from all dairy products (Po0.0001) was significantly lower for lactose-intolerant than tolerant women. Intolerant women were more frequently users of calcium supplements (61%) than tolerant women (39%) (Po0.0001). Heel BMD adjusted for the above-mentioned anthropometric and lifestyle factors was similar for lactose-intolerant vs tolerant women (P ¼ 0.60). Note that only 15.3% of lactose-intolerant women had the CC À13 910 genotype; among lactose-tolerant women the respective prevalence was 18.2% (Table 2) . In the population-based cohort 104 women reported any previous fracture. Of them 14 (13.5%) had the CC À13 910 genotype, which prevalence did not differ from that of 19.3% among 347 women without any fracture history (P ¼ 0.29). The three genotypes did not differ with respect to fracture history (P ¼ 0.30) ( Table 1) . Also lactose-tolerant and intolerant women had experienced fractures in similar frequencies (P ¼ 0.29) ( Table 2) .
Among 52 women with established osteoporosis, the distribution of the three genotypes (CC À13 910 23.1%; CT À13 910 46.2%, TT À13 910 30.7%) was similar as for 59 control women (15.3, 37.3, 47 .4%, respectively) (P ¼ 0.19).
Discussion
In the present study of Finnish postmenopausal women molecularly defined LM did not associate with reduced calcium intake, decreased BMD, osteoporosis or bone fractures. Self-reported milk intolerance was associated with reduced calcium intake from dairy products, but did not affect bone mass, possibly due to frequent use of calcium supplements among lactose intolerant women.
Correlation between self-reported LI and LM is poor; depending on the test used, 11-32% of lactose malabsorbers report no symptoms from lactose containing milk products (Carroccio et al, 1998; de Vrese et al, 2001 ) whereas up to 57% of subjects who experience symptoms of LI may have normal lactase activity (Suarez et al, 1995; Carroccio et al, 1998; Saltzman et al, 1999; de Vrese et al, 2001) . In one study of 323 subjects, 32% of the participants were lactose maldigesters on the basis of H 2 -breath test, but tolerants, while 4% were lactose maldigesters and intolerants ( ¼ complained of symptoms in the hours following lactose load). In contrast, of 49 subjects with self-reported milk intolerance 53% were lactose maldigesters but tolerants ( ¼ did not complain of symptoms after lactose load), 37% were lactose digesters and tolerants and only 5% were lactose maldigesters and intolerants (Carroccio et al, 1998) . These results corroborated quite well with our findings of the population-based cohort, in which 2.4% had the CC À13 910 genotype and self-reported LI; of those with self-reported LI (16.0% of the cohort) only 15.3% had molecularly defined disease. Collectively these studies indicate that many people unnecessarily reduce their milk intake or lactose is not the only constituent of milk causing symptoms of milk intolerance.
A general consensus has existed that if lactose intolerant people significantly reduce their calcium intake, the bone status worsens (Corazza et al, 1995; Honkanen et al, 1997; Goulding et al, 1999; Black et al, 2002) . Di Stefano et al (2002) demonstrated that among 103 healthy men and women (mean age 28 y) the BMD was low only in lactose intolerant malabsorbers who reduced their calcium intake, without any difference between lactose tolerant malabsorbers and absorbers. In a Finnish study of 2025 women, aged 48-59 y, 162 subjects had self-reported LI. In comparison to tolerants they had reduced calcium intake and 2.7-2.4% lower BMD at the lumbar spine and the femoral neck (Honkanen et al, 1996) . Likewise, in a study of Italian postmenopausal women, only LM which resulted in symptoms and reduced calcium intake, decreased BMD (Corazza et al, 1995) . The present results on the women with the CC À13 910 genotype corroborate the previous findings; these women had not reduced their calcium intake and had normal heel BMD. In contrast, although women with self-reported LI reported lower calcium intakes from dairy products, it seems likely that they did not display lower heel BMD because their reported use of calcium supplements was greater than that of women who rated their ability to absorb lactose as good.
Controversial has been the question of whether deficient disaccharidase activity and LM per se affect intestinal calcium absorption and consequently bone mass (Debongnie et al, 1979; Cochet et al, 1983; Tremaine et al, 1986) . Genotyping of the C (À13 910) T polymorphism, reflecting the disaccharidase activity in the gut wall (Enattah et al, 2002 , Kuokkanen et al, 2003 has now made it possible to study the effect of LM per se on intestinal calcium absorption in large study populations. In our recent study young Finnish men with the CC À13 190 genotype had normal serum parathyroid hormone (PTH) levels and normal bone turnover rate which are indicative of normal intestinal absorption of calcium (Enattah et al, 2004) . Furthermore, a group of Austrian postmenopausal women with molecularly defined LM had normal values in a strontium absorption test which well reflects the intestinal absorption of calcium (Obermayer-Pietsch et al, 2004) .
Our results corroborate those of a study from New Zealand, in which the prevalence of LM was similar in females with and without hip fractures (Wheadon et al, 1991) . However, they are not in agreement with those of a previous Finnish study of 11619 women, aged 47-56 y, with 896 subjects having self-reported LI, in which the odds ratio for risk of fracture was 1.33 (1.09-1.62) in lactose intolerant vs tolerant women. The increased risk concerned, however, leg and metatarsal fractures only (Honkanen et al, 1996) . In comparison to healthy controls, the CC À13 910 genotype was not enriched in women with osteoporotic fractures, and also in the population-based cohort women carrying the same genotype did not have experienced fractures in greater numbers than women with the genotypes indicating lactose absorption. The small number of women with established osteoporosis was an obvious limitation in our study as was lack of the information about their calcium intake.
The present results contradict those reported in a recent study of 259 postmenopausal women from Austria (ObermayerPietsch et al, 2004) , in which the C/C À13 910 genotype associated with subjective milk intolerance, reduced milk calcium intake and decreased BMD at the hip and the lumbar spine and predisposed to bone fractures; however, bone turnover rate was not affected (Obermayer-Pietsch et al, 2004) . There are several differences between these two studies. We examined a population-based cohort, whereas in the Austrian study the subjects were participants from a genetic screening study for osteoporosis; it was not described how they were chosen. Our subjects were approximately 10 y older but one would anticipate that any adverse effects of LM on bone would be more apparent in elderly subjects. In the Austrian study 27% of women with the CC À13 910 genotype had known LI compared with 15% in our study. The Austrian women with molecularly defined LM had reduced their milk calcium intake, but total calcium intake was not given. In our study, calcium intake from dairy products only was approximately 700 mg for the CC À13 910 genotype, did not differ from the other genotypes, and was well above the threshold intake of 400 mg, below which calcium supplementation started to improve BMD in one study of women, 6 y or more postmenopausal (DawsonHughes et al, 1990) . Although we were able to measure BMD only in the heel, others have shown peripheral measurements to predict fracture risk even similarly as central BMD measurements (Miller et al, 2002) . Furthermore, a good correlation has existed between the BMDs in the heel and the axial skeleton (r value 0.7), with the calcaneal BMD explaining at least a half of the variance in the BMD of the lumbar spine and the femoral neck (Fordham et al, 2000) . However, in the Austrian study the LCT genotypes alone accounted for only 2-4% of the variance in the BMD of the axial skeleton (Obermayer-Pietsch et al, 2004) , which small contribution we may have been unable to detect using heel BMD measurements only. We also acknowledge that LM may have different effects on BMD in the axial skeleton and at the heel. Finally, the most surprising finding in the Austrian study was that also those with the C/T À13 910 genotype had reduced BMD and trend for increased risk of nonvertebral fractures albeit the disaccharidase activity in the intestinal wall is not reduced in those people (Enattah et al, 2002 , Kuokkanen et al, 2003 , Buning et al, 2004 . Possibly this finding associates only with the poor correlation between LM and LI symptoms.
We conclude, that molecularly defined LM does not significantly contribute to the development of osteoporosis and the occurrence of osteoporotic fractures in Finnish postmenopausal women. Furthermore, LI is not a risk factor for osteoporosis, if calcium intake from diet and/or supplements remains sufficient.
